新冠疫情对精神分裂症患者非新冠住院死亡率的影响:全国性人群队列研究
该研究基于法国全国人群队列,比较新冠疫情期间与非疫情期间精神分裂症患者与非严重精神障碍对照者的非新冠急性住院死亡率与就医可及性差异。结果显示精神分裂症患者90天住院死亡率相对对照升高更显著(aOR=1.18;p<0.001),且ICU及多种躯体疾病入院减少,提示其非新冠急性照护可及性、有效性与安全性恶化更明显。
要点
- 精神分裂症患者非新冠住院90天死亡率疫情期间较对照升高更显著(aOR=1.18;p<0.001)。
- 中毒与损伤、呼吸系统疾病及手术和内科照护场景下死亡率升高更明显。
- 精神分裂症患者ICU及癌症、循环、消化和卒中等躯体疾病入院相对减少。
核心结论
- 新冠疫情期间精神分裂症患者非新冠急性住院死亡率相对对照升高更显著,提示其照护可及性、有效性与安全性恶化更明显。
研究设计与样本
- 精神分裂症患者与年龄性别匹配的无严重精神障碍对照按1:10匹配,共198186例患者与1981860例对照。
- 采用双重差分法与多因素患者水平logistic回归(aOR),调整保险、吸烟、酒精与物质成瘾、Charlson共病评分等因素。
主要发现
- 精神分裂症患者90天住院死亡率较对照升高更显著(aOR=1.18;p<0.001)。
- 中毒与损伤(aOR=1.26;p=0.033)和呼吸系统疾病(aOR=1.19;p=0.008)死亡率升高更明显。
- 手术(aOR=1.26;p=0.008)与内科照护(aOR=1.16;p=0.001)场景下死亡率升高亦更显著。
- 精神分裂症患者相对对照ICU入院及癌症、循环、消化疾病和卒中等躯体疾病入院减少。
临床怎么用
- 在公共卫生紧急事件中应关注精神分裂症患者非新冠急性照护的可及性与安全性。
- 对精神分裂症患者的中毒损伤、呼吸系统疾病及手术和内科照护需加强监测与资源保障。
- 应针对脆弱患者制定专门策略以提升医院应对未来公共卫生紧急事件时的患者安全韧性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
It remains unknown to what degree resource prioritization toward SARS-CoV-2 (2019-nCoV) coronavirus (COVID-19) cases had disrupted usual acute care for non-COVID-19 patients, especially in the most vulnerable populations such as patients with schizophrenia. The objective was to establish whether the impact of the COVID-19 pandemic on non-COVID-19 hospital mortality and access to hospital care differed between patients with schizophrenia versus without severe mental disorder. We conducted a nationwide population-based cohort study of all non-COVID-19 acute hospitalizations in the pre-COVID-19 (March 1, 2019 through December 31, 2019) and COVID-19 (March 1, 2020 through December 31, 2020) periods in France. We divided the population into patients with schizophrenia and age/sex-matched patients without severe mental disorder (1:10). Using a difference-in-differences approach, we performed multivariate patient-level logistic regression models (adjusted odds ratio, aOR) with adjustment for complementary health insurance, smoking, alcohol and substance addiction, Charlson comorbidity score, origin of the patient, category of care, intensive care unit (ICU) care, major diagnosis groups and hospital characteristics. A total of 198,186 patients with schizophrenia were matched with 1,981,860 controls. The 90-day hospital mortality in patients with schizophrenia increased significantly more versus controls (aOR = 1.18; p < 0.001). This increased mortality was found for poisoning and injury (aOR = 1.26; p = 0.033), respiratory diseases (aOR = 1.19; p = 0.008) and for both surgery (aOR = 1.26; p = 0.008) and medical care settings (aOR = 1.16; p = 0.001). Significant changes in the case mix were noted with reduced admission in the ICU and for several somatic diseases including cancer, circulatory and digestive diseases and stroke for patients with schizophrenia compared to controls. These results suggest a greater deterioration in access to, effectiveness and safety of non-COVID-19 acute care in patients with schizophrenia compared to patients without severe mental disorders. These findings question hospitals' resilience pertaining to patient safety and underline the importance of developing specific strategies for vulnerable patients in anticipation of future public health emergencies.
引用
- Boyer L, Fond G, Pauly V, et al. Impact of the COVID-19 pandemic on non-COVID-19 hospital mortality in patients with schizophrenia: a nationwide population-based cohort study. Mol Psychiatry. 2022. PMID: 36207583. doi:10.1038/s41380-022-01803-4
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。